GlobeNewswire·Nov 10, 2026, 8:00 AM ET

Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals initiated dosing for the first patient in the TEMPO-1 Phase 3 registrational study of sutantatug envedotin (CRB-701) for 2L+ oropharyngeal cancer.
Topline data from the CANYON-1 Phase 1b obesity study of CRB-913 showed a mean weight loss of 5% after 12 weeks at a 60 mg daily dose with no plateau observed.
CRB-913 demonstrated a favorable safety profile with fewer & milder gastrointestinal adverse events compared to marketed oral GLP-1 drugs.
Late-breaking CANYON-1 data will be presented at ObesityWeek® 2026 on November 15, 2026.
The TEMPO-1 trial is a randomized study of 250 patients comparing sutantatug envedotin to investigator's choice of capecitabine, cetuximab, or docetaxel.
Corbus anticipates reporting sutantatug envedotin plus Keytruda combination data in first-line oropharyngeal cancer in Q1 2027.
Leonardo Viana Nicacio, M.D., was appointed Chief Medical Officer in August 2026 with over 20 years of pharmaceutical industry experience.
The company reported a net loss of approximately $37.8 million for the quarter ended September 30, 2026, compared to $23.3 million in the prior year period.
Operating expenses increased to $38.8 million due primarily to a $15.0 million development milestone incurred under the CSPC licensing agreement.
As of September 30, 2026, Corbus held $115.3 million in cash, cash equivalents, & investments, expected to fund operations into 2028.